Umbilical cord blood (CB) has been rapidly established as an alternative source of stem cells to bone marrow for allogeneic-related and unrelated hematopoietic transplantation. To date, almost 70 000 CB units are available for transplantation and more than 2000 CB transplants (CBT) have been performed, mostly in children, for the treatment of a variety of malignant and nonmalignant conditions. Considerable experience has been rapidly accumulated in this field and many aspects of CBT have been elucidated, while other questions remain unresolved. A concise review of the clinical results achieved after related and unrelated CBT is presented and discussed.
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Search strategy and selection criteria
Studies selected for this review were identified by searching at MEDLINE (from January 1996 to December 2002) using the Entrez-PubMed web page (http://www. ncbi.nlm. nih.gov/entrez/) from the National Library of Medicine of the NCBI (National Center for Biotechnology Information). The terms searched were umbilical cord blood, transplantation and children or adults. Reviews, editorials, clinical studies and reference lists from relevant articles were reviewed. Abstracts books from the Annual ASH (American Society of Hematology) Meeting from 1996 to 2002 were also searched. English-language publications from authors with recognized experience in the field and clinical studies with a relevant number of patients were selected.
Methods
Outcomes achieved after cord blood transplantation (CBT) in children have been analyzed separately according to the type of donor (related or unrelated) and disease category (malignant or nonmalignant). A separate analysis of CBT outcome in adult patients is performed as well. Malignant diseases treated with CBT in the selected publications were mostly leukemia (acute lymphoblastic and myelogenous leukemia, chronic myelogenous leukemia and juvenile chronic myelogenous leukemia). Other diseases were advanced myelodysplastic syndrome, lymphoma and neuroblastoma. Nonmalignant diseases amenable to CBT were acquired (severe aplastic anemia) or inherited bone marrow failure syndromes, hemoglobinopathies (thalassemia and sickle cell disease), inborn errors (inherited disorders of metabolism, histiocytic disorders and osteopetrosis) and congenital immune deficiencies.
Typing of CBT was usually performed by serology for the HLA-A and -B antigens and by DNA techniques for the HLA-DRB1 alleles. Usually, cord blood (CB) progenitors were thawed and washed following the procedure described by Rubinstein et al. 1 Neutrophil engraftment was defined as the time needed to reach an absolute neutrophil count of at least 500/mm 3 on three consecutive days. In most studies, platelet recovery was defined as the time needed to reach a sustained platelet count of at least 20 Â 10 3 /mm 3 on seven consecutive days in the absence of platelet transfusions. Acute and chronic graft-versus-host disease (GVHD) was scored on the basis of standard criteria. Transplant-related mortality (TRM) was defined as all causes of nonleukemic deaths. Overall survival (OS) was the time between transplantation and death due to any cause, and event-free survival (EFS) was defined as the time between transplant and first event (either relapse or death in complete remission). In most studies, the Kaplan-Meier method or the cumulative incidence curves were used to calculate the probability of neutrophil and platelet engraftment, acute and chronic GVHD, survival and relapse. The prognostic significance of variables was studied by the two-sided logrank test and Cox proportional-hazards model regression.
Overview
Allogeneic bone marrow transplantation (BMT) is currently the only therapeutic approach for several lethal malignant and nonmalignant disorders. The lack of suitable HLA-matched donors has limited its use due to the high risk of life-threatening complications associated with the procedure when immunological identity between donor and recipient is not present. In an attempt to reduce transplant-related toxicity, placental/umbilical CB has emerged as an alternative source of stem cells for patients in need of allogeneic transplantation.
The presence of primitive and committed hematopoietic progenitor cells (HPC) in the CB was initially reported by Knudtzon 2 and later studied by Owaga and other investigators. [3] [4] [5] Broxmeyer et al 6 first addressed in experimental studies the potential application of CB stem cells for clinical transplantation. Despite the fact that the number of functional hematopoietic stem cells in a CB unit is 10 times less than in a BM graft, their proliferative capacity is superior to that of cells in adult BM or peripheral blood. The success of the first related CBT performed in 1988 in a child with Fanconi anemia 7 and further clinical studies [8] [9] [10] confirmed that CB units are capable of providing both hematological and immunological reconstitution after myeloablative therapy. The apparent lesser immunogenicity of the CB was evidenced by the lower incidence of severe GVHD reported after related and unrelated CBT than was expected even in mismatched transplants. 11, 12 Allowing a wider HLA disparity between grafts and recipients and the relatively easy collection procedure of CB units has permitted an enormous expansion of the donor pool and representation of ethnic minorities. CB offers additional advantages over BM in unrelated transplantation such as a low transmission rate of infectious and genetic diseases, the immediate availability of the product avoiding the risks for the donor and loss of registries and a higher probability and considerably faster identification of suitable units. In a recent study by Barker et al, 13 patients receiving CB were transplanted 25 days quicker than those receiving BM. The median time to obtain an unrelated BM donor was 49 days (32-293) compared to a CB search time of only 13.5 days (2-387), plus 30 additional days needed to clear both types of donor.
As the potential of this new source of stem cells was realized, large-scale CB banking was rapidly established worldwide to provide CB units for unrelated transplantation. The first CB bank was founded in 1993 in New York (New York Blood Center, NYBC), where Rubinstein and co-workers first established protocols for collection, processing, cryopreservation and thawing CB units. 1, [14] [15] [16] In a few years, other CB banks were created in different European countries and in several institutions in US. In order to centralize information regarding the availability of units located in CB banks from Europe, Japan, Australia and US, an international cooperative network, Netcord, was founded in 1998.
Placental/umbilical CB is safely and easily collected and stored. To avoid bacterial and maternal cell contamination, the blood remaining in the delivered placenta is drained into sterile blood bags using closed collection systems. Only placental/umbilical CB from controlled pregnancies with negative maternal serology and from full-term normal deliveries is admitted for donation. The presence of transmissible infectious diseases and parental history of genetic disorders do not allow donation. After aliquots are removed for routine testing, units are cryopreserved and stored following similar procedures as those of BM or peripheral blood. [17] [18] [19] CB banks report available units to national and international donor registries (Netcord, National Marrow Donor Program or NMDP, and Bone Marrow Donors World Wide or BMDWW). Each unit is reported with a minimal information that consists of a code number, number of nucleated cells (NC), volume collected and serological HLA-A, -B and -DR1 typing (http://correo. aecientificos.es/cordonumbilical.html).
Netcord, following guidelines of the Foundation for the Accreditation of Hemopoietic Cell Therapy, ensures the quality of CB banking applying minimal standards for collection, storage and for national and international exchanges. An effective communication between donor registries and transplantation centers is ensured through the Netcord virtual office (http://www.netcord.org/ index.html). To date, more than 68 000 CB units are currently registered and available for transplantation in more than 50 banks worldwide and more than 2000 patients (1500 children) have received CBT from these banks (http://www.netcord.org/inventory.gif). Directeddonor banking of CB is performed in some centers under strict conditions and only when another child in the family is currently treated for a genetic disease potentially curable by hematopoietic transplantation. 20 Autologous donation is performed only in a few CB banks in diseases for which gene therapy could be available in the future or if the donor is affected by a condition in which it can be expected that autologous stem cell transplantation could be beneficial. 21 The International Cord Blood Transplantation Registry (ICBTR) and Eurocord are two independent collaborative registries that collect and analyze data of CBT reported from many different transplantation centers. Currently, the ICBTR is part of the International Bone Marrow Transplantation Registry (IBMTR). The IBMTR is a working group of more than 300 transplantation centers located worldwide that contribute detailed data on allogeneic hematopoietic stem cell transplantation to a statistical center at the Health Policy Institute of the Medical College of Wisconsin (Milwaukee, USA). Eurocord is an international registry operating on behalf of the European Blood and Marrow Transplantation group (EBMT) that works in close collaboration with Netcord banks and the EBMT database. Participation is open to European and non-European centers performing CBT.
A review of the literature published by these and other groups (NYBC, University of Minnesota, Duke University Medical Center -DUMC) regarding the safety and efficacy of CB in clinical transplantation and its risks and benefits in comparison with other sources of stem cells is presented.
Clinical results in pediatric-related CBT
Delayed hematopoietic recovery with sustained long-term engraftment occurs after family donor CBT. Several authors have analyzed the factors associated with the rate of engraftment. [22] [23] [24] [25] [26] Wagner and Kurtzberg 23 studied 74 children undergoing a sibling CBT that as of November 1996 had been reported to the ICBTR (Table 1) . Diagnosis included a variety of malignant and nonmalignant diseases (NMD). These patients had a median age of 4.9 years and had received a median of 4.7 (range 1-33) Â 10 7 NC/kg. In 56 cases, grafts were HLA identical or with one antigen difference and 18 presented 2-3 HLA mismatches. A total of 37 children were given growth factors after infusion. For recipients of HLA-identical or one antigen-mismatched transplants, the median time to neutrophil and platelet recovery was 22 (range 9-46) and 51 (range 15-117) days, respectively. The probability of neutrophil engraftment at day 60 was 91%. The use of growth factors did not shorten the time to neutrophil recovery and no correlation was observed between cell dose and engraftment. Eurocord reported comparable results; however, NC dose was observed to influence the rate of hematopoietic recovery. 24, 25 In all, 78 related CBT were analyzed. Characteristics of the recipients are summarized in Table 1 . The probability of neutrophil engraftment at day 60 was 85% when X3.7 Â 10 7 NC/kg was given, while it decreased to 73% when the cell dose was lower. The Eurocord report 26 updating the data of 138 children who underwent a related CBT (114 identical) has confirmed these results (Table 1) . While NC dose was the main factor influencing neutrophil recovery, platelet recovery was associated with the degree of HLA disparity. Faster engraftment was also associated with younger and low-weight recipients. A higher incidence of graft failure was observed among the patients with a nonmalignant condition. [22] [23] [24] [25] [26] The probability of engraftment by 50 days was 69% in patients with NMD vs 100% in those with a malignancy. 22 Several authors have noted a low incidence and severity of both acute and chronic GVHD after sibling CBT. [22] [23] [24] [25] [26] [27] Probabilities of acute GVHDXII, XIII and chronic GVHD were reported as 3, 1 and 6%, respectively, by the ICBTR studies, 22, 23 whereas probabilities of acute GVHDXII and XIII were somewhat higher in the Eurocord series. [24] [25] [26] [27] In sibling CBT, HLA-identical grafts had a lower incidence of acute GVHD compared with HLA nonidentical transplants (9 vs 50%) 24, 25 (Table 1 ). The median follow-up in these studies ranged from 19 to 41 months (Table 1) . One-year probability of OS and mortality after related CBT were reported as 63 and 36%, respectively. 22, 24, 25 For patients transplanted for a malignancy, disease-free survival (DFS) was 46% at 2 years. 26, 27 After relapse, major causes of death were infection and rejection. [24] [25] [26] Favorable prognostic factors for survival in related CBT were lower age and weight, recipient's CMV sero-negative status and HLA identity between the donor and recipient. 22, 24, 25, 27 Matched related CBT had a better 1-year survival than nonidentical transplants (73 vs 33%). 22, 24, 25 Eurocord in collaboration with the IBMTR has compared the outcomes of 113 HLA-identical sibling CBT and 2052 HLA-identical sibling BMT performed in pediatric patients. 26, 27 The characteristics of these patients and transplantation outcomes are summarized in Table 1 . Recipients of CBT were younger, had more ABO incompatibilities, interval from diagnosis to transplant was longer and fewer of them had received prophylactic MTX compared with BMT recipients. Hematopoietic recovery was significantly delayed in the first month after transplant in HLA-identical sibling CBT, but it was similar in both groups thereafter. 26, 27 Acute GVHD grade XII developed less frequently and was less severe in CBT recipients as was chronic GVHD. 25, 26 No significant differences were found in the rate of TRM, OS and 3-year probability of survival between both groups. 26, 27 Relapse was the main cause of death in both groups of patients, followed by infection and hemorrhage in CBT recipients and by GVHD in BMT recipients. 27 Clinical results in pediatric unrelated CBT
The rate of hematopoietic recovery after unrelated CBT has been associated in different studies with the NC and CD34 þ cell dose and the degree of HLA disparity between the donor and recipient. Gluckman 26 analyzed the outcomes of 291 children who underwent an unrelated CBT between October 1988 and March 2000. The characteristics of these patients are summarized in Table 2 . Only 50 patients (17%) had received an HLA-identical graft. With a median of 4.5 (0.6-36) Â 10 7 NC infused per kg median days to neutrophil engraftment were 29 (range 10-60). At day 60, the probability of recovery was 82%. In a previous study from Eurocord in 65 unrelated CBT (13% HLA identical), the probability of neutrophil recovery at day 60 was higher, 87%. 25, 28 Patients had received a median of 3.4 Â 10 7 NC/kg ( Table 2) . In a further analysis of 551 CBT (408 unrelated), HLA identity and cell dose (X3.7 Â 10 7 / kg) have been identified as critical factors for engraftment. 29 Rubinstein et al 30 analyzed 562 unrelated CBT (102 adults) who had been reported to the NYBC between August 1992 and January 1998. The median time to neutrophil and platelet engraftment was 28 (91% probability at day 60) and 90 days (85% probability at day 180), respectively. Variables for improved myeloid engraftment were similar to those in the Eurocord studies. The development of infection after transplant and the presence of GVHD negatively affected platelet engraftment. The degree of HLA disparity had no effect. As of October 1996, 85 patients (mostly pediatric) underwent an unrelated CBT at Duke (n ¼ 63) or Minnesota (n ¼ 22) Universities. 23, 31, 32 Grafts were identical or with one antigen difference in 76 cases. Patients received a median of 4.0 (range 0.3-29.0) Â 10 7 NC/kg and 74% were given G-CSF (Table 2 ). For the entire group, the probability of donor engraftment at day 42 was 94%. At Duke University, the probability of neutrophil recovery was 92% and at Minnesota 82% (median days to engraftment were 20 and 29, respectively). All patients at Duke had received G-CSF until engraftment, but no patient was treated before day 21 at Minnesota. Cell dose (43 Â 10 7 /kg), early G-CSF treatment and no irradiation-based conditioning had positively influenced neutrophil recovery. The Minnesota group has recently analyzed 102 unrelated CBT performed in 88 children and 22 adults receiving a median of 3.1 Â 10 7 NC and 2.8 Â 10 5 CD34 þ cells per kg. The probability of neutrophil engraftment at day 42 was 88% and was strongly correlated with CD34 þ cell dose (Table 2) . A trend to more rapid recovery was observed when using G-CSF. Reported incidences of acute GVHDXII, severe acute GVHD and chronic GVHD after unrelated CBT have ranged between 32-46%, 9-22% and 0-25%, respectively (Table 2) . Patient age and HLA disparity affected independently the frequency and severity of GVHD. 30 GVHD was less severe in HLA-identical transplants, but no correlation with the number of HLA mismatches was found. In contrast, for other investigators the degree of HLA disparity had no influence in the risk of acute GVHD, while a CMV sero-negative status lowered this risk. 25, 28 The probability of 1-and 2-year OS ranged from 29 to 58% and from 40 to 47%, respectively. 23, 25, 33, 34 The major causes of death were infection, pulmonary disease and relapse. Prognostic factors were cell dose X3.7 Â 10 7 /kg and degree of HLA disparity. 23, 25, 30, 34 One-year survival was 41% when NC dose was X3.7 Â 10 7 and 22% when less cells were given. 25, 28 Other favorable variables were recipient CMV, sero-negative status, 25, 28, 34 lack of severe GVHD, 34 younger age 25, 30, 34 and weight o20 kg. 25, 28 Patients treated for an NMD had a better 2-year survival than did those with a malignancy (60 vs 38%). 34 In the study of Wagner et al, 34 dose of CD34 þ cells was significantly associated with the rate of TRM and survival. Survival at 1 year was 70% when X1.7 Â 10 5 CD34 þ cells per kg were infused; however, 1-year TRM was as high as 80% when o1.7 Â 10 5 CD34 þ cells per kg were infused. 34 A matched pair analysis comparing the outcomes after unrelated CBT and unrelated BMT was conducted by Barker et al 35 at Minnesota University. CBT recipients were age-and disease-matched with BMT patients who received either cyclosporine-A (CSA) plus MTX (26 pairs) or T-cell depleted grafts (31 pairs) as GVHD prophylaxis (Table 2 ). All the CBT recipients had received prophylactic CSA plus prednisone. Most CBT were nonidentical (1-2 HLA differences). A slower neutrophil recovery was noted after CBT compared with both BMT groups. Probability of recovery at day 45 and graft failure were similar in CBT and BMT pairs. Despite an increased HLA disparity within the CBT recipients, the probability of engraftment, GVHD and survival were comparable between unrelated CBT and unrelated BMT.
Studies of CBT in children with acute leukemia
Studies of CBT in children with acute leukemia (AL) are summarized in Table 3 . [36] [37] [38] [39] Eurocord analyzed 102 children with AL treated with either a related or unrelated CBT. 37 Hematopoietic recovery was delayed in unrelated CBT compared with family donor CBT. Cell dose X3.7 Â 10 7 /kg was associated with a faster engraftment in both groups. Other favorable factors for neutrophil recovery in related CBT were age o6 years, weight o20 kg, no administration of prophylactic MTX and good-risk disease. 36, 37 Michel et al 38 have studied 95 pediatric children who had received an unrelated CBT for the treatment of acute myeloid leukemia. Grafts were identical in eight cases and 44 had one HLA disparity (Table 3) . Neutrophil engraftment was 78% at day 60 and was favorably correlated with NC dose X4.4 Â 10 7 /kg. No significant differences in the probabilities of acute GVHDXII, XIII and chronic GVHD between related and unrelated CBT were found in the Eurocord series 36, 37 ( Table 3) . In related CBT, a higher risk of GVHD was significantly associated with HLA disparity (probability of acute GVHD was 26% in HLA-identical and 75% in nonidentical CBT) and recipient's CMV sero-positive status. NC dose o3.7 Â 10 7 /kg increased the risk of acute GVHD in the unrelated group. 37 One-year OS for patients with AL treated with CBT has ranged between 42 and 45% 35, 36 (Table 2 ). In a recent report from Eurocord analyzing 690 patients (203 adults) undergoing unrelated HLA-identical (11%) or nonidentical (43% with 1 antigen mismatch) CBT, 2-year OS was 46% in children and 26% in adults. 40 TRM at day 100 was 34% for the entire group. 40 Outcomes did not differ according to the type of donor, 36, 37 but were mainly associated with disease stage at transplant. [34] [35] [36] [37] [38] [39] Survival was 55% in standard-and 32% in high-risk ALL patients and 33% in high-risk AML patients. 34 Poor-risk patients showed an increased rate of both 1-year TRM and 2-year relapse.
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The 2-year EFS and 1-year TRM were 49 and 34%, respectively, in good-risk patients vs 8 and 65%, respectively, in poor-risk patients. Other unfavorable factors for outcome were HLA disparate graft, NC dose o3.7 Â 10 7 / kg, age 46 years and weight 420 kg 37 ( Table 3 ). The rate of leukemia relapse has been reported as 9% at day 100, 17% at day 180 and 26% at 1 year after transplant. 30 In the different series, the 2-year probability of relapse ranged between 42 and 49% after related CBT and between 37 and 47% after unrelated CBT (Tables 1-3 ). Status at transplant was the major predictor of relapse in most of the studies (Tables 1-3 ). In the NYBC report, 1-year probability of relapse was 19% for patients transplanted in the early stage of disease, increasing to 24 and 35% for those in intermediate or advanced stage, respectively. 30 Eurocord has reported a 2-year probability of relapse of 77% for poor-risk and 31% for good-risk patients. 36 Similarly, the Minnesota group found a rate of relapse of 10% in standard-and 43% in high-risk ALL and 47% in high-risk AML. 34 Other predictors of relapse were younger age, 34 NC dose o3.7, 26 severe GVHD 30 and type of leukemia (AML). 30 In AML patients, the 2-year probability of relapse was 29%. 38 Hematological status at transplant had a strong prognostic influence in children with leukemia, but showed no association with the number of HLA disparities between donor and recipient. The 2-year EFS was 59 and 50% in CR1 and CR2 patients, respectively, and 16% in children with more advanced disease. 38 At the NYBC, the outcomes of 210 unrelated BMT and 296 unrelated CBT recipients with AL have been compared. 41 In the BMT group, 62 and 32% of the recipients had HLA-identical or 1-antigen disparate grafts. Among the CBT recipients, only 6% were HLA identical with their donors and 41% had 1-antigen disparity. CBT had similar survival but less acute GVHD than BMT. Higher TRM and lower survival were noted after CBT with 41 antigen disparity compared with HLA identical or with 1 disparity transplants. Survival was related to the degree of HLA disparity. The 3-year OS was 68% in recipients of 39 analyzed data of 541 children with AL undergoing an unrelated CBT (n ¼ 99), or an unrelated BMT (n ¼ 262), or an unrelated T-cell depleted BMT (T-BMT) (n ¼ 180) (Table 3) . Statistical adjustments for prognostic factors were performed to compare these three heterogeneous groups of patients, using the BMT as the reference group. Long-term analysis included patients surviving more than 100 days. In the first 100 days, the BMT group had a higher incidence of acute GVHD, the T-BMT group had a higher incidence of relapse and the CBT group had a higher incidence of TRM. The CBT group had delayed hematopoietic recovery, higher engraftment failure and less acute GVHD compared with the BMT group. Relapse during this time was associated in CBT recipients with younger age, AML and advanced disease. Outcomes after 100 days were comparable between the CBT and the BMT groups. Advanced disease at transplant influenced the rate of relapse and mortality in all groups. At 2 years, no significant differences in outcomes between unrelated CBT and unrelated BMT were found ( Table 3) .
Studies of CBT in children with NMD
Reports of CBT in patients with NMD are scarce in the literature and most of them have been published in abstract form (Table 4) . Compared with recipients of related CBT treated for a malignancy, higher rates of engraftment failure and OS, and lower TRM had been reported for patients with NMD. [22] [23] [24] [25] [26] [27] In a group of 33 patients with thalassemia (Th) and 11 with sickle cell disease (SCD) treated with a related CBT (41 HLA identical), the probability of neutrophil engraftment at day 60 was 89%. 42 Eight patients (seven Th and one SCD) failed to engraft and seven had mixed chimerism. All patients survived but the probability of EFS at 2 years was 79% for Th and 90% for SCD patients. The use of prophylactic MTX and conditioning regimen with busulfan plus cyclophosphamide were associated with lower probability of engraftment and EFS, while NC dose was not a predictor of outcome.
The results of CBT in patients with bone marrow failure syndromes (BMFS) vary according to the type of donor. 43 In 19 patients transplanted with related CB probability of neutrophil recovery at day 60 and EFS at 1 year were 81 and 67%, respectively. Favorable factors for outcome were age o7 years, weight o24 kg and recipient's CMV seronegative status. Among 14 children treated with an unrelated CBT, the probability of engraftment was 36% and only one patient was alive at 1 year. 43 Among 21 other patients with a BMFS who were given an unrelated CBT, the patients with Fanconi anemia had the highest incidence of engraftment failure (33%) and the worst survival rate. 44 Survival was better in children younger than 2 years (OS 80%).
Based on the historical data in the literature, the results of unrelated CBT in primary immunodeficiencies are comparable to those of unrelated BMT, allowing a complete hematological and immune reconstitution. [44] [45] [46] [47] OS at 2 years has been reported as 69%. Faster hematopoietic recovery was associated with age o1.4 years and weight o9 kg, while immune recovery was related to NC dose. 47 Outcomes of patients with inborn errors treated with CBT seem comparable to that of BMT. 44, 46, 48 In 14 patients with Hurler syndrome given an unrelated CBT, the probability of EFS at 2 years was 86%. 48 
Unrelated CBT in adults
Despite initial concerns regarding engraftment, the results of unrelated CBT in adult patients demonstrate sustained short-and long-term hematopoietic recovery ( Table 5 ). The Eurocord has performed the largest study including adults undergoing an unrelated CBT. 26, 49, 50 Among 108 patients analyzed, 102 had received mismatched CB units. The median number of NC and CD34 þ cells infused were 1.7 (0.2-6) Â 10 7 and 0.8 (0.01-8.9) Â 10 5 /kg, respectively. Neutrophil recovery occurred at a median of 32 days. The probability of neutrophil and platelet recovery was 81% at day 60 and 65% at day 180, respectively. Graft failure occurred in 18% of patients at risk. Engraftment was faster in those patients receiving NC dose X1.7 Â 10 7 /kg and without chronic myelogenous leukemia (CML). Other groups have reported a higher rate and speed of recovery in adults given an unrelated CBT. Most of these patients had received HLA nonidentical CB grafts for the treatment of hematological malignancies. [51] [52] [53] The median time to neutrophil and platelet recovery ranged from 22 to 27 days and from 58 to 69 days, respectively. Graft failure was diagnosed in 0-8% of patients. The probability of engraftment at day 42 was 96% in 68 adult CBT reported by Laughlin et al. 51 Engraftment was related to NC dose, but not with the number of CD34 þ cells infused. In the study of Sanz et al, 53 all 22 patients had engrafted at day 60 after transplant, and recovery was also related to CB cell dose. In this cohort of patients, a single conditioning therapy (busulfan plus cyclophosphamide plus thiotepa) and a unique GVHD prophylaxis (cyclosporine A plus prednisone) were used; all units had X1 Â 10 7 NC/kg and all patients had received a common supportive treatment.
Reported incidences of acute and chronic GVHD in adults undergoing unrelated CBT have been higher than those reported in children, but lower than after unrelated BMT. 51 The probability of acute GVHDXII and XIII at day 100 have ranged between 41 and 63% and between 20 and 32%, respectively ( Table 5 ). The probability of chronic GVHD at 2 years was 38%. No predictors of GVHD have been found.
Outcomes after unrelated CBT in adults are comparable to those obtained after unrelated BMT 55, 56 and poorer than those obtained in children. 40, 49 Best results have been achieved in young adults in the early phase of their disease. 54 Among adult patients undergoing unrelated CBT, the rate of TRM at day 100 has ranged between 35 and 54% (Table 5) . At day 180, Eurocord has reported TRM of 56% in adults vs 32% in children. 26, 49, 50 TRM was related to NC dose and HLA identity. At day 100, TRM was 75% among patients receiving o1 Â 10 7 NC/kg and 30% in those receiving X3 Â 10
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. Patients given HLAidentical grafts had 29% TRM at day 100 vs 34, 45 and 50% for those given units with 1, 2 or X3 HLA disparities, respectively. Rates of OS and EFS after unrelated CBT in adults varied in the different studies, being 30% in the study of Laughlin et al 51 (Table 5) . Disease status at transplant and NC dose are main prognostic factors. EFS at 1 year was 39% in good-risk patients (CML in chronic phase and AL in early stage) vs 17% for patients with AL in advanced stage. When NC dose was 42 Â 10 7 /kg, EFS at 1 year was 33%, while only one of 11 patients receiving o1 Â 10 7 per kg survived. 26, 49, 50 Laughlin et al 51 have found an association between the rate of survival and CD34 þ cell dose (EFS at 3 years was 20% when o1.2 Â 10 5 /kg CD34 þ cells were given, while it was 38% when X1.2 Â 10 5 /kg CD34 þ cells were infused). In this study, survival was not related to NC dose, degree of HLA mismatching, older age (440 years), type of malignant disease, grade of acute GVHD or recipient's CMV serological status. 51 Sanz et al 53 found that an age less than 30 years and good-risk disease status were associated with better DFS (73% DFS in younger patients vs 27% in older patients) with no effect of cell dose, degree of HLA mismatching and recipient CMV status.
Eurocord has reported a preliminary study comparing the outcomes of adult patients with AL who had undergone either an unrelated CBT or an unrelated BMT. 55 Neutrophil recovery was delayed after CBT and despite increased number of HLA disparities, probabilities of relapse, OS and EFS after CBT were comparable to those observed after BMT. Neutrophil recovery was associated to CB cell dose. According to this study, CB units with 41 Â 10 7 NC/kg and no more than two HLA disparities should be considered an acceptable alternative to HLA-matched unrelated BMT for adults with AL. 55 Immunological recovery after related and unrelated CBT Niehues et al 45 have studied the immune reconstitution in 14 related and 49 unrelated CBT. The median age of these patients was 4 years, 26 had HLA-identical grafts and 21 had received MTX. Among these patients, 33 had a malignant disease and 14 an immunodeficiency. Neutrophil recovery had been achieved at a median of 21 days. The phenotype of reconstituting cells was studied at several time points after transplant. Normal values of NK and B cells were detected at 3 and 6 months after transplant, respectively. NK cell recovery occurred earlier in patients with hemoglobinopathies and those older than 5 years. CD8T cells recovered at a median of 8 months and CD3 þ and CD4 þ cells at 12 months. A related transplant, recipient's CMV sero-positive status and higher cell dose were associated with faster T-cell recovery, while this was delayed in the presence of acute GVHD. Other studies have reported similar results; 31, 33, 57 however, no correlation was found between NC dose and time to immune recovery 33 (Table 6 ). At 3 months after CBT immunoglobulin levels were normal, while numbers and function of T cells were significantly decreased, 56 in vitro responses to mitogen stimulation were detectable at 3 months after unrelated CBT and became normal at 6 months. 31, 33, 57 Moretta et al 58 have studied 23 age-and donor-matched pairs of CB and BM recipients. Recovery of lymphocyte number and function was comparable in CBT and in BMT recipients. In a recent report, Talvensaari et al studied a group of patients treated with an identical sibling CBT and a reference group of age-and GVHD-matched BMT patients. Demographic data are shown in Table 6 . Reconstitution of T-cell diversity was studied by the size of b-chain complementarity determining region 3 (CDR3) and by quantitation of TCR rearrangement excision circles (TRECs). During the first year after transplantation, TCR repertoires were highly abnormal and TREC values low in both groups. After 2 years or more after transplantation, an efficient and durable recovery of thymic function and normal T-lymphocyte diversity were achieved in the CBT recipients.
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Conclusions CB HPC provide hematopoietic and immunological reconstitution after myeloablative therapy in allogeneicrelated and unrelated transplants. Currently, it is a valuable alternative to BM as a source of progenitor cells for clinical transplantation, offering similar outcomes and not more overall toxicity than BMT, at least in children. Faster identification of a compatible unit, immediate availability of cryopreserved CB progenitors, absence of risks for the Compared with BMT, delayed neutrophil and platelet recovery, higher risk of graft failure and higher incidence of TRM during the first 100 days occurs after CBT. Death is due mainly to infection, hemorrhage and regimen-related toxicity. Therefore, the major current barrier to a wider use of CBT is the limited cell dose of CB units, especially for adult recipients. Cell dose is predictive of myeloid engraftment and survival. According to Eurocord, faster hematopoietic recovery and better survival are achieved when X3.7 Â 10 7 NC/kg are given. While this breakpoint only reflects the median number of cells infused, this group has suggested that 2 Â 10 7 NC/kg could be the minimum cell dose necessary for achieving optimal results, and grafts with o1-1.5 Â 10
7 NC/kg probably should not be used. 49 In a recent study from the Minnesota group, the 1-year TRM after CBT was 15% when 42.7 Â 10 5 CD34 þ cells per kg were given. Mortality increased to 29% when CD34 þ cell dose was between 1.7 and 2.7 Â 10 5 /kg and it was as high as 68% when o1.7 Â 10 5 CD34 þ cells per kilogram were infused. 34 Recommendations from this group are to use CB units containing at least 1.7 Â 10 5 CD34 þ cells per kilogram and when several units are available, discard grafts with lesser number of cells. Other parameters of CB hematopoietic content such as the number of colony-forming cells and the number of nucleated red blood cells could be better predictors of engraftment, but this issue needs further investigation. 60, 61 Administration of G-CSF had no impact on engraftment.
An increasing interest in the use of CB for transplantation has prompted extensive research in the in vitro and in vivo biological characteristics of neonatal blood cells in order to optimize and extend its clinical applications. Many of these efforts are currently focused on the ex vivo expansion and genetic manipulation of CB stem cells. [62] [63] [64] [65] Ex vivo expansion of HPC and transplantation with multiple CB units are strategies that would allow increasing cell dose in CBT. Despite the existence of some reports exploring the clinical application of these procedures, it is still too early to evaluate their real benefits. [62] [63] [64] [65] In a recent trial performed at the University of Minnesota, 37 patients (25 adults and 12 children) with hematological malignancies received a fraction of CD34 þ selected and ex vivo expanded CB cells along with the remainder fraction of unmanipulated CB cells. 65 A median of 0.99 Â 10 7 /kg NC (expanded plus nonexpanded) were infused. All patients received CSA plus prednisone as GVHD prophylaxis and G-CSF from day 0. The median time to neutrophil engraftment was 28 days . At a median follow-up of 30 months OS was 35%. A correlation between the number of CD34 þ cells infused and engraftment was found, but apparently this strategy did not improve the kinetics of engraftment using nonexpanded CB cells. 65 For several authors, an additional critical factor determining hematopoietic recovery and outcome in unrelated CBT is the HLA identity between CB graft and recipient. The influence of the number of NC in the CB and the degree of HLA disparity would mutually interact in the engraftment. Increasing the number of cells decreases the influence of HLA mismatching and the number of cells necessary for engraftment would be lesser in HLA-identical CBT. 29 Wagner et al 34 have suggested that for each degree of HLA disparity, there is a critical cell dose below which survival is significantly impaired, particularly in recipients of CB units with X2 HLA disparities.
The frequency and severity of GVHD after CBT is lower than after BMT, even when HLA disparate CB grafts are given. Initial concerns were that the better immunological tolerance to CB progenitor cells could predispose patients to an increased risk of leukemia relapse compared with BMT. However, similar EFS and rate of relapse have been reported in recipients of CB and BM transplants. GVHD is lower in HLA-identical CB grafts compared with nonidentical transplants, but no other predictors have been identified.
Allogeneic CBT from either related or unrelated donor is a feasible procedure able to cure a significant proportion of children and adults with AL, especially if they are transplanted in a favorable phase of disease. 54 Besides disease status, favorable prognostic factors are HLA identity, NC dose and recipient's CMV sero-negative status.
Unrelated CBT is a feasible procedure for children with BMFS and inborn errors, but the limited number of patients in these disease categories undergoing CBT and the short follow-up suggests that additional experience is needed to determine the benefits of these alternative therapies. CBT is a valid option for treating congenital immune deficiencies, offering results at least as good as other stem cell sources. In patients with HBP, the results are in favor of CB directed-banking in families in whom a transplant might be indicated. 20 In children, long-term outcomes of CBT are similar to that of other stem cell sources, but in adult patients poorer results are achieved. The indication of CBT to adults is usually restricted because of the relatively low numbers of NC in CB units. Engraftment is delayed with higher early TRM and although the incidence of GVHD is lower than after BMT, it is higher compared with CBT in children. However, long-term EFS seem to be comparable to BMT, especially in young patients with early disease. The choice of units containing large number of cells and patients in good disease status might improve results.
In summary, umbilical CBT is a curative alternative for patients with cancer and several nonmalignant conditions lacking an appropriate BM donor. Current recommendations are searching BM donor registries and CB bank simultaneously. When both types of donors are identified, clinicians generally indicate BM over CB. If a BM donor is not available and multiple CB units exist, experts recommend basing the selection of CB unit on cell dose (NC and CD34 þ cells), ABO compatibility and extent and class of HLA incompatibility. 40 When two or less HLA disparities exist, graft selection should be based principally on the CD34 þ cell dose. 34 However, the criteria for choosing CB over BM are changing over time as we learn more about this source of stem cells. The final choice of HPC must take Talvensaari   59 into account the degree of HLA disparity, urgency of the transplant, total nuclear cell and CD34 þ cell contents of the graft.
